<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test</h1>
  <ul>
<li>PRESS RELEASE - 09/15/2025, 09:00 AM EDT Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test First-ever fully automated, sample-to-result, cartridge-based companion diagnostic test approved in the US for colorec</li>
<li>The Idylla™ CDx MSI Test aids in identifying eligible microsatellite instability-high (MSI-H) colorectal cancer (CRC) patients, who may benefit from treatment with OPDIVO® (nivolumab) alone, or in combination with YERVOY</li>
<li>The Test runs in a single-use cartridge, requiring less than three minutes of hands-on-time and delivering straightforward results in under three hours.</li>
<li>“Achieving FDA approval for our Idylla™ CDx MSI Test represents a key milestone for Biocartis," said Michael Korn, M.D., Chief Medical and Scientific Officer at Biocartis.</li>
<li>With its speed, accuracy, and automation, the Idylla™ CDx MSI Test offers a powerful solution that enables clinicians to make timely, confident and data-driven treatment decisions when every moment counts.”</li>
<li>“It underscores our commitment to helping oncology patients receive the right therapy without delay and the recent CheckMate-8HW data reinforce the critical importance of accurate MSI-H/dMMR testing in colorectal cancer.</li>
<li>“The approval of this new MSI companion diagnostic for patients with colorectal cancer is a meaningful achievement from our collaboration with Biocartis and a strong reflection of our Precision Medicine strategy at Brist</li>
</ul>
<p><a href="https://finance.yahoo.com/news/press-release-biocartis-nv-biocartis-130000684.html">Source</a> · 2025-09-15T13:00:00+00:00</p>
</body>
</html>